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ABSTRACT
Objectives: The illicit use of anabolic steroids among
the gym population continues to rise, along with the
number of steroid using clients attending harm
reduction services in the UK. This presents serious
challenges to public health. Study objectives were to
account for the experiences of anabolic steroid users
and investigate how ‘risk environments’ produce harm.
Methods: Qualitative face-to-face interviews with 24
users of anabolic steroids engaged with harm
reduction services in the UK.
Results: Body satisfaction was an important factor
when deciding to start the use of anabolic steroids.
Many users were unaware of the potential dangers of
using drugs from the illicit market, whereas some had
adopted a range of strategies to negotiate the hazards
relating to the use of adulterated products, including
self-experimentation to gauge the perceived efficacy
and unwanted effects of these drugs. Viewpoints, first-
hand anecdotes, norms and practices among groups of
steroid users created boundaries of ‘sensible’ drug use,
but also promoted practices that may increase the
chance of harms occurring. Established users
encouraged young users to go to harm reduction
services but, at the same time, promoted risky
injecting practices in the belief that this would enhance
the efficacy of anabolic steroids.
Conclusions: Current steroid-related viewpoints and
practices contribute to the risk environment
surrounding the use of these drugs and may
undermine the goal of current public health strategies
including harm reduction interventions. The level of
harms among anabolic steroid users are determined
by multiple and intertwining factors, in addition to the
harms caused by the pharmacological action or injury
and illness associated with incorrect injecting
techniques.
INTRODUCTION
There is growing interest within public
health in understanding how dynamic rela-
tionships between people who use drugs and
the surrounding environment can affect the
production or reduction of drug-related
harm.1 In this approach, focus changes from
individual-level factors alone to social situa-
tions and environments embedding the use
of drugs. The present study explores the
illicit use of anabolic steroids for the purpose
of human enhancement among the gym
population in the UK. The emphasis is that
harm among users is contingent not just on
pharmacologically active substances in ‘ana-
bolic steroid’ products but also on the ‘risk
environment’—a space where multiple
factors (physical, social, economic, policy)
intertwine to affect the chance of harm
occurring.2
There has been reporting of harms relat-
ing to anabolic steroids, including adverse
reactions such as acne, hair loss, gynaecomas-
tia, disruption of growth, damage to tendons
and ligaments, testicular atrophy, erectile dys-
function, liver damage (especially with oral
products) and cardiovascular events.3 It has
also been reported in the literature that ana-
bolic steroids may cause aggressive behav-
iour.4 Severity of these effects would appear
to be dose dependent.
Additional harms relate to the route of
administration given that many users inject at
least some of their drugs,5–7 leading to
Strengths and limitations of this study
▪ Advances our understanding of the risks posed
by the use of anabolic steroids by exploring the
relationship between harm in individual users
and the surrounding environment.
▪ This study recruited a broad cross section of ana-
bolic steroid users, proving access to accounts of
the experiences of this group of drug users.
▪ Findings reflect those users attending harm
reduction services. Users who choose not to
engage with these services may have a different
risk profile.
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concerns regarding incorrect injection technique and
transmission of blood borne viruses through the sharing
of injecting equipment.8 A recent study of anabolic
steroid injectors in England and Wales, reported that
8.9% had shared injecting equipment.6 Of considerable
concern for public health is the identiﬁcation of 1.5%
being HIV positive, 9% with antibodies to the hepatitis B
core antigen (anti-HBc) and 5% to hepatitis C virus
(anti-HCV). In the case of hepatitis B, biological samples
were only tested for core antigen identifying those that
had been exposed to hepatitis B, rather than the level of
users who are carriers of the virus. Still, it is noteworthy
that the results of the study indicate comparable levels of
HIV prevalence between injectors of anabolic steroids
and intravenous heroin injectors in England and Wales.
Studies in the USA and in Sweden suggest that steroid
use may be associated with the use of recreational
drugs.9 10 In the UK, prevalence of cocaine use among
steroid users is substantially higher than the comparable
general population.6 However, large scale studies with an
in-depth focus on the causal relationship between the
use of steroids and recreational drugs are required.
The complex polypharmacy adopted by many users of
these drugs poses additional risks. Common regimens
include the concurrent usage of various drugs for
enhancement purposes including a range of anabolic
agents, stimulants and an array of drugs used as self-
treatment of steroid-induced side effects5–7 11 through to
the use of dietary and herbal supplements that may be
contaminated with undeclared harmful substances.12 13
While accounts of such potential health harms asso-
ciated with anabolic steroids advance the understanding
of the direct harms posed by various active substances,
along with their route of administration, they offer little
insight into the social processes and environmental
factors exhibiting relations of risk and enablement.1
Empirical qualitative studies show that users exchange
anabolic steroid-related information on methods to
reduce or avoid adverse effects.14 As a consequence,
many users ignore or perceive the risk of steroid usage
as relatively minor.7 15–17 Steroid users who seek the
support of peer users but avoid social censure by
keeping their use of drugs a secret from others may also
serve as a mechanism that promotes harm.18 By contrast,
shared norms and practices in local groups of steroid
users may also establish lines between what is seen as
‘sensible’ drug usage and what is not. One study found
that the use of ephedrine (a stimulant) and nalbuphrine
(an opioid) for enhancement purposes were seen by
some steroid users as irresponsible risk taking because
these drugs were compared to amphetamines and
heroin, respectively.19 This article reports on ﬁndings of
an interview study conducted to explore the experiences
of anabolic steroid users and investigate microenviron-
ments and macroenvironments relating to physical and
social risks in this particular population of people who
use drugs. In addition to what is currently known about
the hazards posed by the pharmacotoxicological actions
of anabolic steroids, this perspective can be used to iden-
tify additional and complex risk patterns in steroid users.
METHOD
This article is based on qualitative interviews with 24
users of anabolic steroids conducted between 2009 and
2011. The research was part of a study of harm reduc-
tion services in areas of England and Wales available to
users of anabolic steroids. Such individuals have been
recognised as a growing client population in harm
reduction services across the UK.8 20
Recruitment
A mix of purposive and convenience sampling were
used in order to select a cross section of steroid users.21
Seven steroid users were recruited from ﬁxed-site needle
and syringe programmes; three from an outreach service
in gyms; nine from steroid clinics providing harm reduc-
tion interventions designed speciﬁcally for users of ana-
bolic steroids; one from a gym and, four offenders from
a prison. Staff in harm reduction services approached
steroid users and enquired if they were willing to partici-
pate with interviews taking place in a private room
within these facilities. Further, a gym manager
approached gym members and informed them of the
research. In this case, the interview was conducted in
the locker room out of earshot from other members.
Offenders agreed to partake after they had been
informed about the study by the head of the physical
education department. These interviews were conducted
without the presence of prison ofﬁcers to allow for
offenders to speak conﬁdentially. The purpose of
recruiting from different venues was to see whether
there were any differences between steroid users attend-
ing harm reduction services and users recruited at other
venues; however, it emerged that all respondents had
been in contact with such services at some time point
and interviews did not reveal any signiﬁcant differences.
Sample characteristics
The oldest respondent was 61 and the youngest 21 (mean
age 34 years). All respondents reported previous or
current use of anabolic steroids and nine reported the
use of synthetic growth hormones. The majority of
respondents had begun their use of anabolic steroids
around the age of 25, although three had begun at the
age of 16. The sample was relatively experienced as many
had taken a number of steroid cycles (typically consisting
of courses of drugs ranging from 6 to 12 weeks followed
by a period of abstinence). The sample comprised men
only, for which there are several explanations:
▸ Research shows that the majority of steroid users are
men.5 6 22
▸ There is a stigma associated with female anabolic
steroid use, at least in part, due to the signiﬁcant mas-
culinising effect of steroids and the societal expecta-
tions of gender identity.23 24
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▸ Four respondents were recruited from a prison exclu-
sively for men.
Data generation
Interviews were conducted by AK, lasting from 30 to
75 min. Following the collection of basic demographic
information, interviews were semistructured covering the
following topics based on available literature (1) body
(dis)satisfaction; (2) motivations for steroid usage; (3)
patterns of steroid use, sources of steroid-related infor-
mation and accounts of health harms and (4) users’
experiences with harm reduction services.
During the collection of data, the interviewer identi-
ﬁed himself as a public health researcher conducting a
study about the use of and policy towards anabolic
steroids. It was made clear to respondents that the inter-
viewer had no afﬁliation to either health or criminal
justice services and that their anonymity was guaranteed.
Furthermore, many harm reduction services were
located in a different area than the institution the inter-
viewer was afﬁliated with, this was made clear to respon-
dents, which most likely made steroid users consider the
interviewer as an ‘objective outsider’. It is believed that
this facilitated a trusting and honest interaction, with
open sharing of personal accounts.
Most interviews were recorded, and subsequently tran-
scribed by AK, except when prison regulation prohibited
the use of electronic devices, or when respondents felt
uncomfortable about discussing sensitive issues relating to
anabolic steroids. In such cases, a written record was com-
piled immediately after the interview. Written interview
records were subjected to thematic content analysis to
identify and verify main themes (accounted for below).25
The analytical process conducted as the study progressed
was led by AK with input from JM in order to conduct
internal checking by comparing results.26 This process
continued until themes provided explanatory accounts of
the data. University ethical approval was obtained.
RESULTS
A signiﬁcant ﬁnding across all accounts was that a pre-
dominant reason to work out and take anabolic steroids
was to enhance physical appearance, resonating with
previous research suggesting that body dissatisfaction
among men can lead to a desire to increase muscle
mass leading to the use of anabolic steroids.17 27 Of
importance here is that steroid users typically expressed
that there was a limit to what could be achieved ‘natur-
ally’; that is training without using steroids, and that this
belief appeared to have a direct inﬂuence on decisions
to use drugs:
I knew I had pushed my body to the limit of what I natur-
ally could and I wanted to take that a little bit further.
(Steroid user aged 35)
Of equal importance is the increased body satisfaction
when other people took notice of the gains that they
had made, highlighting that societal norms regarding
the ‘perfect body’ create an environment which may
affect the continuation of steroid use in some people:
People who hadn’t seen me since school would come up
to me and go, ‘Oh my God, you look massive, you look
fantastic’, and it’s a big hype. It’s stupid because it’s what
is inside that counts, how you are as a person, but there
is no way around it, if someone comes up to you and
says, ‘You look fantastic’, ‘You look good’, ‘You used to be
skinny, but look at the size you have now’, it’s an amazing
thing, and to think that I have done that myself by train-
ing hard. Because I train hard. (Steroid and growth
hormone user aged 36)
In addition to this dominant theme, two broad
themes emerged from the analysis:
1. Working through words and phrases, made during
initial reading of the interview records, resulted in a
list of categories, including: safety of illicit market
products, contents of illicit market products, lack of
information about illicit market products, changes
regarding the illicit market (over time), trust of illicit
suppliers and the use of illicit market products to
determine their effects (selected examples). Based
on a reﬁnement of these categories, a reduced list of
categories was compiled: uncertainties relating to the
illicit market, viewpoints towards illicit suppliers and
practices relating to the use of illicit market products.
This led to the ﬁnal coding framework, resulting in
the following theme: the dangers of using drugs from
the illicit market, which were unknown to many
whereas others had developed practices to negotiate
hazards posed by these drugs (which were in them-
selves creating risk).
2. Reﬁnement of initial analysis created another list of
categories: steroid users warn users about health
harms, users encourage needle and syringe pro-
gramme attendance, different steroids are perceived
as ‘safe’ versus ‘unsafe’, users promote certain inject-
ing practices and users rely on information from peer
users (selected examples). This list was further
reduced, providing categories for the initial coding
framework: users promote health among users, risk
relating to dissemination of information among users
and promotion of steroid-related practices among
groups of users. From here the ﬁnal coding frame-
work was derived, resulting in the following theme:
the social structures pertaining to steroid use, which
enable the transfer and dissemination of anabolic
steroids-related information of dubious accuracy and
validity.
This article describes these two themes, neglected to
date in this area of research.
Perceptions of illicit market products
This and other studies22 28 have found that products
claiming to contain anabolic steroids are readily access-
ible from the illicit market. Yet the issue of
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contaminated, adulterated and misbranded drugs, along
with its impact on the behaviour of users, remains a
neglected area of study.
Whereas a few of the respondents expressed uncer-
tainties pertaining to the composition and sterility of
drugs obtained from the illicit market, the majority
remained ignorant, or at the very least, unconcerned,
regarding the associated risks. However, to other users in
this study, the implication was that it was difﬁcult for
them to know exactly what pharmacologically active sub-
stance(s) was in the vials they had obtained, as well as
the amount of active ingredients. This undermined their
ability to plan out their regimes:
The biggest change I’ve seen in steroids is the fact that
when I started using them [in the late 1980s], everything
you got was pharmaceutical grade. It was from a chemist
or a pharmacy. It was brought in from abroad or it was
from this country. They were genuine Organon, Bayer, all
these famous drug companies and they all came pack-
aged and you knew exactly what you were using. It’s com-
pletely changed now. You can’t get anything
pharmaceutical grade, everything is ‘underground’.
(Steroid user and gym owner aged 45)
Another uncertainty was the confusion caused by ana-
bolic steroids sold under ﬁctitious product names such
as ‘Cutstack’. This seemed to have direct impacts on the
process of obtaining information about speciﬁc types of
anabolic steroids:
Certain steroids on the [illicit] market are called differ-
ent names to what they are called in the book [the
so-called ‘steroid handbook’ by William Llewellyn,29] and
some steroids aren’t in the book. So, I go on the Internet
for that information, but each site says different things
about it. (Steroid user aged 22)
Of note is that these insecurities did not seem to deter
users from purchasing and using such products.
However, it did appear to lead to various practices being
adopted in an attempt to mitigate these uncertainties.
Signiﬁcantly in this respect, a number of steroid users
said that getting their hands on drugs of a ‘sound
quality’ came down to ﬁnding ‘someone that could be
trusted’ and hence many preferred to buy from ‘local
dealers’ rather than online retailers (steroid user and
competing bodybuilder aged 45). In many cases, users
would dismiss speculation regarding the quality and
safety of the drugs because they trusted the person who
had sold them:
I’ve always used the same guy, and I never had no issues
with him. I always use the same person. I never had bad
‘gear’ from him. (Steroid user aged 22)
However, given that users in many cases cannot deter-
mine accurately the quality of such products, illicit man-
ufacturers and suppliers are able to use this to their
advantage12; for example, through the deliberate
misbranding of vials to increase their proﬁt. This was of
concern to some:
I’ve heard horror stories about dealers that I talk to...
there’ll be a tray of vials and they’ll ask, ‘what are you
after?’ And they say, ‘well there’s the bottles, there’s the
labels, take whatever labels you need and just stick them
on the bottles.’ There might be some active ingredient in
them but you just can’t know for sure what you’re
getting. (Steroid user and gym owner aged 45)
Distinct to this group was that many respondents
described practices relating to self-experimentation to
gauge the effects of anabolic steroids. In fact, self-
experimentation was widely accepted as an approach to
gain ﬁrst-hand experience of the effects of these drugs:
I think it takes a couple of courses of steroids to be able
to understand how they work properly...the ﬁrst time I
took steroids I probably accumulated a lot more body fat
than I had anticipated, but it’s all part of a learning
process. (Steroid user aged 35)
This approach was used on products from the illicit
market to see what the effect would be and hence to
assess their quality:
Maybe you could put counterfeit stuff in a normal bottle.
You wouldn’t know, but you do ﬁnd out the difference
after you’ve ﬁnished your course and you are not getting
the results you should be getting. I think that’s a risk you
take, it comes in life, it comes everywhere. (Steroid user
aged 27)
These accounts highlight that for many the main
concern regarding an unregulated market with products
of dubious provenance is either being ‘ripped off’ or at
the very least failing to make the desired gains. The
potential for serious adverse health consequences due
to poor manufacturing of products is not generally per-
ceived as a major issue.
Peer users and steroid knowledge: risk reduction?
In describing their experiences of anabolic steroids, it
became clear that the practices, viewpoints and experi-
ences of other users signiﬁcantly affected risk behaviour,
both positively and negatively. It seemed that experi-
enced users would act as a form of regulator within the
gym population; for instance by providing steroid-related
information, advising users not to adopt the ‘high-dose’
regimes used by competing bodybuilders and persuad-
ing young people not to take steroids until they were
older:
I’ve always told teenagers that have asked me if they can
take steroids and stuff, that it’s at your own risk. You
might be 5′ 7″ now, that might be as tall as you’re going
to get [given that anabolic steroids may shunt the
normal pattern of growth,8] but if you don’t take them,
you might be 5′ 10″. That’s always been my best plan and
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that works. Because they think, ‘Oh shit, I don’t want to
end up 5′ 7″ when I could be taller’. (Steroid user and
gym owner aged 45)
In addition, a number of experienced steroid users
told how they encouraged younger users to go to harm
reduction services such as needle and syringe pro-
grammes to obtain sterile injecting equipment in order
to prevent the transmission of blood borne viruses.
Overall, belonging to peer and social groups of steroid
users meant having access to and being inﬂuenced by
information and advice with the potential to reduce the
harms of steroid use. In these ways, norms and practices
within environments may serve to establish boundaries
by constructing ‘sensible’ and ‘responsible’ drug usage.
By contrast, viewpoints, shared norms and perceived
wisdom of users also appeared to have the potential to
increase risk. The widely accepted anabolic steroid
‘knowledge base’, passed on from user to user, is largely
derived from informal self-experimentations, along with
users’ interpretations of the ‘literature’ which, in many
cases, was restricted to anecdotes and peer accounts of
their respective self-experimentation. In instances where
robust scientiﬁc evidence was considered this was nor-
mally via a third party’s interpretation of ﬁndings. Here
scientiﬁc studies, including animal or in vitro experi-
ments, with limited ﬁndings can be wildly extrapolated
or ﬁndings ‘cherry-picked’ to support existing beliefs or
rationalise perceived effects. Even so, in the group of
steroid users in this study, there was a general sense of
‘trust’ in advice from peers:
I go to the gym, that’s where everyone goes to train. So
for everyone who’s actually doing the same thing, they’re
all in one spot. You can get all of the information you
need. Why shouldn’t I trust them? Because if you look at
them, and think, ‘well he must be doing something right
because look at the shape of him’. They look really really
good so why not trust them? (Steroid user aged 27)
The importance of this knowledge was clear, as steroid
users told how they used it to decide which types of
drugs and dosages to use. It was also used to distinguish
between what types of anabolic steroids were considered
‘safe’:
I have heard ‘Deca’ [Deca-Durabolin®; nandrolone
decanoate] and ‘Sustanon’ [Sustanon® 250; containing a
testosterone blend] to be the safest steroids there are,
whether that is true I don’t know. I have heard it off
books, off people, off the Internet. (Steroid user aged 23)
The ‘proper’ use of anabolic steroids, was considered
to entail variations of high doses of multiple types of
anabolic steroids, provided the regimen complied with
the current commonly held beliefs of synergistic efﬁcacy,
typically referred to as ‘stacking’. Moreover, the use of
ancillary drugs to treat or prevent steroid induced side
effects was seen as an important aspect of ‘responsible’
steroid usage. In fact, the use of ancillary drugs was per-
ceived as the ‘sensible’ choice, rather than the reduction
of steroid dosages to avoid side effects in the ﬁrst place.
Again, it was clear that self-experimentation was an
essential part of the process:
I know personally when my body requires hCG [human
chorionic gonadotropin; taken by steroid users to trigger
the production of testosterone in the body at the end of
a steroid course]...It’s hard to explain, but, for example,
if you have problems with erection and things like that,
then I know personally when my body needs hCG and
that’s usually when I take it. I know from personal experi-
ence if I need it or not. (Steroid user aged 35)
Shared guidelines among steroid users also extended
to the administration of these drugs. On the one side
users described injecting practices which were broadly in
keeping with harm reduction messages pertaining to
intramuscular injections, such as injection into the large
muscle groups like the gluteus maximus (buttocks) or
vastus lateralis (thigh) to promote diffusion and minimise
the risk of abscess formation.5 The rotation of injection
sites to avoid damage and complications was also out-
lined. However, injections in the smaller muscles, such as
the triceps brachii (back of the arms), were also pro-
moted among users as ways to achieve a ‘direct effect in
the speciﬁc muscle’ (steroid user aged 27)—referred to
as ‘spot injections’ among steroid users. There is no evi-
dence to support this action and the likelihood of
injection-related complications is increased. This practice
highlights the ‘conﬂicts’ between information dissemi-
nated among users (promoting the perceived efﬁcacy of
‘spot injections’) and the contradictory harm reduction
message from needle and syringe programmes (injecting
only into large muscle groups).
Read together, multiple factors inﬂuenced steroid-
related behaviour in this group of users, with peer inﬂu-
ence being mentioned in most cases. Some appeared to
have a positive inﬂuence on the risk posed by this behav-
iour. However, it was clear that being part of the steroid
using culture ultimately seemed to create a sense of
safety among steroid users regarding their use of these
drugs, which appears to be misplaced.
DISCUSSION
Main findings, strengths and study’s limitations
The overarching ﬁnding of this study was that bodily
ideals, the structure, availability and function of the
illicit market, accessibility of information through both
local and global information networks (in gyms or via
the Internet), along with steroid users’ perceptions of
the veracity and value of this information, can increase
the chance of harm occurring in this speciﬁc drug using
population.
Despite attempts among steroid users to gauge the
efﬁcacy and hence ‘quality’ of anabolic steroids obtained
from the illicit market it is impossible for users to know
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exactly what substances they are taking,28 30 impeding
the successful self-management of risks in users. The
ﬁndings suggest a need to raise awareness regarding the
potential health consequences of adulterated drug
usage, not only in harm reduction services but also
among generic health professionals who may come into
contact with steroid users. Steroid users retrieved infor-
mation about the use, effects and route of administra-
tion of anabolic steroids from a number of sources
including peer users within the gyms in the local envir-
onment and the Internet, a practice exhibiting risk as
well as harm reduction. Information regarding anabolic
steroids was used within a strategy of risk management
which, in turn, provided a sense of safety in users. This
is broadly in keeping with previous work highlighting
that the planned use of anabolic steroids, as opposed to
the ‘abuse’ of these drugs, was used as a strategy to avoid
or minimise harm.14 However, important uncertainties
relating to this information undermines attempts to
manage the risks associated with these drugs. It may be
that as a consequence of the multiple sources, and sheer
volume, of data about anabolic steroids, in particular on
the Internet, users become less critical about the accur-
acy of this information.31 This suggests that unambigu-
ous advice is required. However, without control of the
illicit market and the development of a robust evidence
base this will not be possible.3 8
The strength of the study was the recruitment of a
cross section of steroid users, providing access to
accounts of their perceptions and experiences. The col-
lected data has added further insights into the environ-
ments and risk associated with the use of anabolic
steroids. Such insights are of importance in the planning
and delivery of public health initiatives. A limitation of
this study is that all respondents had been in contact
with harm reduction services. There is currently insufﬁ-
cient data to describe accurately potential differences
between different groups of steroid users for example in
terms of risk patterns, however, those attending harm
reduction services presumably represent a group of
more cautious drug users, particularly with regard to
injecting behaviour, compared to ‘hidden’ populations
of users who avoid contact with health services. A survey
conducted among members of three gyms in the South
Wales Region, that were reported to be popular venues
for steroid using gym goers, found that 20% of partici-
pating steroid users revealed syringe sharing with other
users whereas 86% reported to never having had a
medical check.32 Although there is no mention of harm
reduction service attendance in this sample this might
possibly be an example of a group of steroid users
engaging in more risky behaviour than the sample
studied here. That being said, all respondents in this
present study clearly stated that they relied predomin-
antly on the dissemination of information among peer
groups of steroid users to inform their drug-taking
behaviour suggesting that ﬁndings of this study extend
beyond users in contact with harm reduction services.
Implications for harm reduction practice
Harm reduction service workers are faced with the chal-
lenge of delivering advice, education and interventions
in ways that will result in a reduction of overall harm
even though steroid users are heavily affected by physical
and social risk environments that may, in many cases,
increase the chance of harm occurring; a point which
came across in this study.
As a greater number of steroid using clients access
harm reduction services, speciﬁc knowledge and
resources will be required to deliver effective harm
reduction interventions for this group of drug users.20
Signiﬁcantly in this respect, this study found that
whereas all steroid users had obtained sterile needles
and syringes from services only about half of them, pre-
dominantly those gaining access to steroid clinics,
reported seeking additional information from these pro-
grammes with few reporting that they sought informa-
tion about how to use anabolic steroids in the least
harmful way. Here, the availability of knowledge within
groups of steroid users seemed to act as a barrier to
information from health authorities, which resonates
with previous ﬁndings that health services are not
usually seen as credible sources of information.7 14 16 22
Services must identify more appropriate ways of provid-
ing credible information that will be valued and result in
positive behaviour change. The two current foci of user
information, the internet and the experienced steroid
user within the gym culture, should be further explored
as methods of engagement and dissemination of harm
reduction information.
It is possible that having harm reduction service provi-
ders with speciﬁc knowledge about the issues relating to
the use of anabolic steroids and other drugs used for
human enhancement purposes would increase the
chances of delivering effective health intervention and
hence challenge some of the hazardous behaviour
described here. Harm reduction services have the ability
to identify and respond to novel drug trends, such as the
increasing number of clients using drugs for human
enhancement including anabolic steroids, synthetic
growth hormones and new products such as the skin
tanning drug melanotan II.12 However, the mainstay of
most harm reduction services is needle and syringe dis-
tribution, along with information on safe injecting.
While this approach aims to reduce the transmissions of
blood borne viruses from the sharing of injecting equip-
ment it does not help protect steroid users from a range
of health harms caused by adulterated and substandard
drugs, suggesting a need to focus on harm reduction
messages relating to the use of products from the illicit
market.
CONCLUSIONS
The potential harms of anabolic steroids are not only
the result of their pharmacological active substances or
route of administration, but also the result of numerous
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factors that are situationally and structurally dependent
on the environment in which the use of anabolic ster-
oids occur. These include the acceptance of using drugs
from the illicit market as well as relying on uncertain
information from peers. Current harm reduction inter-
ventions face barriers caused by viewpoints, norms and
practices among steroid users. Strategies in public health
are currently needed that are capable of functioning
within existing environments, in which steroid users par-
ticipate, in order to promote and protect health.
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